Journal: Fundamental Research

Article Title: Intranasal delivery of rotigotine to the brain for treating Parkinson’s disease

doi: 10.1016/j.fmre.2025.02.004

Figure Lengend Snippet: Synthesis and characterization of Rotigotine-loaded nanoparticles (RT-NPs). (a) Scheme for showing the preparative procedures for RT-NPs. The different mass ratio of rotigotine to PEG- b -PPG- b -PEG (average Mn 12,000) are set as seven groups, with the reaction volume hold constant in each group, the polymer maintaine a consistent concentration at 10 mg/mL in (b) and rotigotine concentration is fixed around 1 mg/mL in (c). (d) The mass ratio, reaction volume, and polymer concentration are consistent with (b) except for the use of polymer with a lower molecular weight (Mn 8400). (e) Entrapment efficiency of RT-NPs in (b)-(d).

Article Snippet: Dichloromethane was purchased from Chinasun Specialty Products Co., Ltd. Poly (ethylene glycol)-block-poly (propylene glycol)-block-poly(ethylene glycol) (PEG- b -PPG- b -PEG) with average molecular weights of 12,000 and 8000 were purchased from Shanghai Energy Chemical Co., Ltd. and Aladdin Co., Ltd. Dimethyl sulfoxide (DMSO) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. Acetonitrile and Trifluoroacetic acid were purchased from Shanghai J&K Scientific Ltd. Rotigotine was purchased from Shanghai yuanye Bio-Technology Co., Ltd. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) hydrochloride was obtained from Dalian Meilun Biotech Co., Ltd. Phosphate buffer saline (0.01M, pH 7.2–7.4) was purchased from Solarbio Biotech.

Techniques: Polymer, Concentration Assay, Molecular Weight

Journal: Fundamental Research

Article Title: Intranasal delivery of rotigotine to the brain for treating Parkinson’s disease

doi: 10.1016/j.fmre.2025.02.004

Figure Lengend Snippet: Synthesis and characterization of RT-NPs. (a) TEM image and (b) size distribution histogram of RT-NPs. (c) Hydrodynamic size distribution profile of RT-NPs. (d) UV–Vis-NIR absorbance spectra of rotigotine and RT-NPs. (e) Hydrodynamic size and (f) UV–Vis-NIR absorbance spectra of RT-NPs in aqueous solution recorded against time.

Article Snippet: Dichloromethane was purchased from Chinasun Specialty Products Co., Ltd. Poly (ethylene glycol)-block-poly (propylene glycol)-block-poly(ethylene glycol) (PEG- b -PPG- b -PEG) with average molecular weights of 12,000 and 8000 were purchased from Shanghai Energy Chemical Co., Ltd. and Aladdin Co., Ltd. Dimethyl sulfoxide (DMSO) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. Acetonitrile and Trifluoroacetic acid were purchased from Shanghai J&K Scientific Ltd. Rotigotine was purchased from Shanghai yuanye Bio-Technology Co., Ltd. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) hydrochloride was obtained from Dalian Meilun Biotech Co., Ltd. Phosphate buffer saline (0.01M, pH 7.2–7.4) was purchased from Solarbio Biotech.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: The flow diagram of selecting Rotigotine-related AEs from FAERS database

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: Clinical characteristics of reports with rotigotine from the FAERS database

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: Time to onset of Rotigotine-associated adverse events and Weibull distribution analysis

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: The signal strength of AEs related to rotigotine at the SOC level in the FAERS database was detected by four algorithms

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: Signal Strength of top20 AEs of Rotigotine at the PT Level in FAERS Database

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: The top 30 most frequent adverse events for rotigotine excluding common medication co-usage at the PT level from FAERS data

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

doi: 10.1186/s40360-025-00911-5

Figure Lengend Snippet: The top 30 signal strength of adverse events of rotigotine ranked by the number of case reports at the PTs level in FAERS database

Article Snippet: Concurrently, in a German clinical trial assessing the efficacy and tolerability of rotigotine for treating RLS led by Karin Stiasny-Kolster et al., a total of 84 skin reactions were documented among 66 (9.6%) of the patients.

Techniques: